This paper is in the following e-collection/theme issue:

Digital Health Reporting Standards, Quality and Transparency in e-Research (96) Policy and Policy Proposals (136) Evaluation of XR and Spatial Computing (64) Augmented Reality (incl. Google Glass) Applications (107) Clinical Integration of XR and Spatial Computing (47) Tutorials on XR and Spatial Computing (2) Tutorial (70)

Published on in Vol 26 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/56790, first published .
Reporting Guidelines for the Early-Phase Clinical Evaluation of Applications Using Extended Reality: RATE-XR Qualitative Study Guideline

Reporting Guidelines for the Early-Phase Clinical Evaluation of Applications Using Extended Reality: RATE-XR Qualitative Study Guideline

Reporting Guidelines for the Early-Phase Clinical Evaluation of Applications Using Extended Reality: RATE-XR Qualitative Study Guideline

Authors of this article:

Johan H Vlake1, 2 Author Orcid Image ;   Denzel L Q Drop1 Author Orcid Image ;   Jasper Van Bommel1 Author Orcid Image ;   Giuseppe Riva3, 4 Author Orcid Image ;   Brenda K Wiederhold5 Author Orcid Image ;   Pietro Cipresso3, 6 Author Orcid Image ;   Albert S Rizzo7 Author Orcid Image ;   Barbara O Rothbaum8 Author Orcid Image ;   Cristina Botella9, 10 Author Orcid Image ;   Lotty Hooft11 Author Orcid Image ;   Oscar J Bienvenu12 Author Orcid Image ;   Christian Jung13, 14 Author Orcid Image ;   Bart Geerts15 Author Orcid Image ;   Evert-Jan Wils2 Author Orcid Image ;   Diederik Gommers1 Author Orcid Image ;   Michel E van Genderen1 Author Orcid Image ;   RATE-XR Expert Group16
Article Authors Cited by (2) Tweetations (1) Metrics
All Time | Last Month | Last Six Months | Last Year
The XR Research Digest The XR Research Digest @XrDigest

How can XR research improve transparency in healthcare? New consensus-driven research introduced the RATE-XR guideline for better reporting of XR studies. https://t.co/OZ7QHRBgGh #vr #xr #virtualreality

5:27 PM · Dec 01, 2024

0
0